HighTech CallerGene Therapy Market Trends, Cost Structure Analysis, Growth Opportunities And Forecast To 2025Facts of WeekGene Therapy Market research report provides the up-to-date industry data and industry future trends, allowing you to categorize t… Continue reading
CRISPR Human Knockout Screens Identify New Target for ALSGenetic Engineering & Biotechnology NewsA team at Stanford University School of Medicine has used CRISPR/Cas9 technology to gain new insights into the genes that might represent new targets for t… Continue reading
FierceBiotechCRISPR Human Knockout Screens Identify New Target for ALS | GENGenetic Engineering & Biotechnology NewsU.S. researchers have used CRISPR/Cas9 screens to identify genes that may protect against or promote the toxicity of protein aggregates … Continue reading
The Brain Tumour Charity (press release) (blog)Researchers discover a new target for immunotherapyThe Brain Tumour Charity (press release) (blog)The preclinical study, recently published in the Science Translational Medicine, was led by researchers fro… Continue reading
The Brain Tumour Charity (press release) (blog)Researchers discover a new target for immunotherapyThe Brain Tumour Charity (press release) (blog)The preclinical study, recently published in the Science Translational Medicine, was led by researchers fro… Continue reading
The Ohio State University NewsStudy: Adult human immune cells have stem cell-like function that stimulates healingThe Ohio State University NewsCOLUMBUS, Ohio – A new study led by researchers at The Ohio State University Wexner Medical Center shows tha… Continue reading
OncLive |
Perl Highlights Latest CAR T-Cell Therapy Advances
OncLive OncLive: CAR T-cell therapy was recently named ASCO’s Cancer Advance of the Year. How has this treatment changed the paradigm for hematologic malignancies, such as ALL? Perl: The CD19-directed therapies have really changed that process, whether it’s … |
OncLive |
Perl Highlights Latest CAR T-Cell Therapy Advances
OncLive OncLive: CAR T-cell therapy was recently named ASCO’s Cancer Advance of the Year. How has this treatment changed the paradigm for hematologic malignancies, such as ALL? Perl: The CD19-directed therapies have really changed that process, whether it’s … |